APS Aptose Biosciences Inc
- 0.870
- -0.020-2.25%
Aptose Biosciences Inc News
Aptose Biosciences Faces Nasdaq Delisting Challenge
Aptose Announces Receipt of Deficiency Notice From Nasdaq
Aptose Announces Results From Annual and Special Meeting of Shareholders
Press Release: Aptose Announces Results From Annual and Special Meeting of Shareholders
H.C. Wainwright Maintains Aptose Biosciences(APTO.US) With Buy Rating, Maintains Target Price $7
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Express News | Aptose Biosciences Shares Move Higher; Traders Circulate Zacks Article Titled "Aptose Biosciences Upgraded to Buy: What Does It Mean for the Stock?"
H.C. Wainwright Maintains Aptose Biosciences(APTO.US) With Buy Rating, Cuts Target Price to $7
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Biosciences Concludes Agreement, Announces Update
Aptose Biosciences Looks to Raise $4.43M in a Direct Offering
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Biosciences Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Aptose Biosciences, Lowers Price Target to $6
Aptose Biosciences Analyst Ratings
Buy Rating for Aptose Biosciences on Tuspetinib's Promising AML Study and Synergistic Potential
Express News | Aptose Biosciences Inc : Canaccord Genuity Cuts Target Price to $6 From $15
Earnings Call Summary | Aptose Biosciences(APTO.US) Q1 2024 Earnings Conference
Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript
Aptose Biosciences | 10-Q: Quarterly report
